EMA Authorised: Neuraceq (florbetaben (18F)) — Life Molecular Imaging GmbH

View source ↗

Summary

EMA authorised Neuraceq (florbetaben-18F) by Life Molecular Imaging GmbH for imaging beta-amyloid plaques in Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• NEURACEQ (Florbetaben F 18)

Snippet

Status: Authorised. Therapeutic area: Radionuclide Imaging;Alzheimer Disease. MAH: Life Molecular Imaging GmbH. Decision date: 21/11/2025